← All companies

KYTX

Kyverna Therapeutics, Inc.

KYTX Nasdaq Biological Products, (No Diagnostic Substances) EDGAR ↗

$7.51

+0.02 +0.27%

Key statistics

from XBRL data in SEC filings

Market cap

$457M

Revenue (TTM)

—

Net income (TTM)

-$156M

EPS (TTM)

$-3.27

P/E ratio

—

Dividend yield

—

Free cash flow

-$154M

Cash

$32.2M

Total assets

$257M

Gross margin

—

52-week range

$2.80 – $13.67

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Entered a material agreement; Regulation FD disclosure Jul 27, 2026 8-K Entered a material agreement Jul 9, 2026 8-K Shareholder vote results Jun 2, 2026 8-K Director or officer change; Other events May 18, 2026 10-Q Quarter ended 2026-03-31 May 12, 2026 8-K Results of operations (earnings release) May 12, 2026 8-K Other events May 4, 2026 8-K Regulation FD disclosure Apr 22, 2026 8-K Regulation FD disclosure Apr 22, 2026 8-K Regulation FD disclosure Apr 20, 2026 10-K Fiscal year ended 2025-12-31 Mar 26, 2026 8-K Results of operations (earnings release) Mar 26, 2026 8-K Director or officer change; Other events Feb 24, 2026 8-K Director or officer change; Other events Feb 3, 2026 8-K Results of operations (earnings release); Director or officer change Jan 12, 2026 8-K Entered a material agreement; Other events Dec 18, 2025 8-K Regulation FD disclosure Dec 15, 2025 8-K Regulation FD disclosure Dec 15, 2025 10-Q Quarter ended 2025-09-30 Nov 12, 2025 8-K Results of operations (earnings release) Nov 12, 2025 8-K Entered a material agreement; Took on a direct financial obligation; Regulation FD disclosure Nov 3, 2025 8-K Regulation FD disclosure Oct 29, 2025 8-K Regulation FD disclosure Oct 29, 2025 8-K Director or officer change Sep 25, 2025 10-Q Quarter ended 2025-06-30 Aug 12, 2025 8-K Results of operations (earnings release) Aug 12, 2025 8-K Director or officer change; Other events Jun 30, 2025 8-K Shareholder vote results Jun 3, 2025 10-Q Quarter ended 2025-03-31 May 13, 2025 8-K Results of operations (earnings release) May 13, 2025 8-K Entered a material agreement Mar 27, 2025 10-K Fiscal year ended 2024-12-31 Mar 27, 2025 8-K Results of operations (earnings release) Mar 27, 2025 8-K Other events Jan 21, 2025 8-K Regulation FD disclosure Jan 13, 2025 8-K Director or officer change Nov 26, 2024 10-Q Quarter ended 2024-09-30 Nov 13, 2024 8-K Results of operations (earnings release); Director or officer change Nov 13, 2024 8-K Director or officer change; Other events Oct 21, 2024 8-K Director or officer change; Other events Sep 16, 2024